UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019122
Receipt number R000022109
Scientific Title A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer
Date of disclosure of the study information 2015/09/26
Last modified on 2021/03/22 17:24:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer

Acronym

A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer

Scientific Title

A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer

Scientific Title:Acronym

A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer

Region

Japan


Condition

Condition

gynaecological cancer

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

efficacy of aprepitant plus palonosetron against that of palonosetron for CINV in patient receiving moderately emetic cancer chemotherapy

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

complete response (CR, defined as complete absence of emetic events) in the delayed phase

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

control group (standard antiemetic therapy:0.75 mg palonosetron administered intravenously on day 1 and 6 mg dexamethasone administered intravenously on day 1 and 4 mg dexamethasone administered orally on days 2 and 3).

Interventions/Control_2

aprepitant group (oral administration of 125 mg aprepitant 90 minutes before administration of the chemotherapy drug on day 1 and of 80 mg on days 2 and 3 and 0.75 mg palonosetron administered intravenously on day 1 and 6 mg dexamethasone administered intravenously on day 1 and 4 mg dexamethasone administered orally on days 2 and 3)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

20 years of age with gynaecological cancer who were scheduled to receive single-day chemotherapy with a carboplatin target area under the concentration curve of 5, and paclitaxel at 175 mg/m2. All patients had an Eastern Cooperative Oncology Group performance status of 0-2, adequate renal function, adequate hepatic function, and adequate marrow function.
All patients provided written informed consent for their participation in the study.

Key exclusion criteria

receipt of any agent that could affect the study results (such as an antiemetic, steroid, or pimozide) before the start of chemotherapy; symptomatic brain metastasis; gastro-intestinal obstruction or any other condition that could provoke nausea and vomiting; and a known allergy or severe reaction to any of the study drugs.

Target sample size

76


Research contact person

Name of lead principal investigator

1st name Daiki
Middle name
Last name Ogishima

Organization

Juntendo Nerima Hospital

Division name

Department of Obstetrics and Gynecology

Zip code

177-8521

Address

Takanodai 3-1-10, Nerima-ku, Tokyo, Japan

TEL

03-5923-3111

Email

daiki@juntendo.ac.jp


Public contact

Name of contact person

1st name Yayoi
Middle name
Last name Sugimori

Organization

Juntendo Nerima Hospital

Division name

Department of Obstetrics and Gynecology

Zip code

177-8521

Address

Takanodai 3-1-10, Nerima-ku, Tokyo, Japan

TEL

03-5923-3111

Homepage URL


Email

ysugi-junten@umin.ac.jp


Sponsor or person

Institute

Juntendo Nerima Hospital

Institute

Department

Personal name



Funding Source

Organization

Juntendo Nerima Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo Nerima Hospital

Address

Takanodai 3-1-10, Nerima-ku, Tokyo, Japan

Tel

03-5923-3111

Email

ysugi-junten@umin.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 09 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 09 Month 01 Day

Date of IRB


Anticipated trial start date

2010 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 09 Month 26 Day

Last modified on

2021 Year 03 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022109


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name